ÂÜÀòÂÒÂ×

Steven Havlicek has worked for two companies in their career. From 2017 to present, they have been employed at Neurona Therapeutics, where they have held the roles of Principal Scientist, Scientist II, Scientist I, and Associate Scientist. In these roles, they have developed protocols for neural cell therapies, identified strategies to enhance potency, persistence, and purity of off-the-shelf products, established assays to identify and quantify cellular impurities, and applied small molecule based screens to optimize differentiation protocols. From 2014 to 2017, they were a Postdoctoral Fellow at the Genome Institute of Singapore, where they characterized and improved CRISPR/Cas9 systems, and harnessed the power of high throughput technologies such as deep sequencing to evaluate the performance and specificity of gene edits in human cells.

Steven Havlicek obtained their Doctor of Philosophy (Ph.D.) in Neuroscience and Stem Cell Biology from FAU Erlangen-Nürnberg in 2014, having started the program in 2010.